One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
https://doi.org/10.1182/blood.v126.23.814.814
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Dec 3, 2015 |
 Citations: 4 |
Affiliation: Willamette Valley Cancer Institute and Research Center, Huntsman Cancer Institute, Mayo Clinic, City Of Hope National Medical Center, Rocky Mountain Cancer Centers, Hematology Oncology Associates, Virginia Commonwealth University, The University of Texas MD Anderson Cancer Center, Compass Oncology, Seagen (United States), Virginia Cancer Specialists, Arizona Oncology, Texas Oncology, Washington University in St. Louis
Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
